Selective RET inhibitors, including selpercatinib and pralsetinib, are associated with significantly fewer toxicities and have shown promise in RET-mutated MTC and RET fusion-positive PTC (Wirth et al. 2020, Subbiah et al. 2021b). Here, RET is linked to medullary thyroid gland carcinoma.